India’s Push for Biosimilars: Affordable Access to Life-Saving Drugs

In oncology and autoimmune care, I often see patients forced to discontinue treatment because the original biologic drug is too expensive. This is where biosimilars — near-identical versions of complex biologics — are changing lives in India.

Recently, Indian pharma companies have accelerated launches of biosimilars for cancer (trastuzumab, bevacizumab), diabetes (insulin analogs), and rheumatoid arthritis (adalimumab). For my patients, this means a high-quality alternative at a fraction of the cost — sometimes cutting expenses by 30–70%.

Of course, challenges remain. Some patients ask, “Doctor, is this biosimilar as good as the original?” Trust is built slowly, and real-world evidence from Indian cohorts will be critical. We also need stronger education for both doctors and patients on safety, interchangeability, and pharmacovigilance.

Still, biosimilars are not just about economics. They represent a chance for equity: ensuring a cancer drug or an insulin pen isn’t limited to the wealthy, but accessible across India.